These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19464540)

  • 21. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.
    Torres JF; Lyerly DM; Hill JE; Monath TP
    Infect Immun; 1995 Dec; 63(12):4619-27. PubMed ID: 7591115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.
    Hussack G; Arbabi-Ghahroudi M; van Faassen H; Songer JG; Ng KK; MacKenzie R; Tanha J
    J Biol Chem; 2011 Mar; 286(11):8961-76. PubMed ID: 21216961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucosylation Drives the Innate Inflammatory Response to Clostridium difficile Toxin A.
    Cowardin CA; Jackman BM; Noor Z; Burgess SL; Feig AL; Petri WA
    Infect Immun; 2016 Aug; 84(8):2317-2323. PubMed ID: 27271747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.
    Xie J; Zorman J; Indrawati L; Horton M; Soring K; Antonello JM; Zhang Y; Secore S; Miezeiewski M; Wang S; Kanavage AD; Skinner JM; Rogers I; Bodmer JL; Heinrichs JH
    Clin Vaccine Immunol; 2013 Apr; 20(4):517-25. PubMed ID: 23389929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.
    Ryan ET; Butterton JR; Smith RN; Carroll PA; Crean TI; Calderwood SB
    Infect Immun; 1997 Jul; 65(7):2941-9. PubMed ID: 9199470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant lipoprotein-based vaccine candidates against C. difficile infections.
    Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P
    J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Murine Neonatal Fc Receptor Is Required for Transport of Immunization-Induced C. difficile-Specific IgG to the Gut and Protection against Disease but Does Not Affect Disease Susceptibility.
    Amadou Amani S; Lang GA; Ballard JD; Lang ML
    Infect Immun; 2021 Sep; 89(10):e0027421. PubMed ID: 34097471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and verification of an enzyme-linked immunosorbent assay for the quantification of toxoid A and toxoid B from Clostridioides difficile.
    Anwar S; Bryan D; Rigsby P; Dougall T; Rijpkema S
    J Immunol Methods; 2021 Jan; 488():112917. PubMed ID: 33221460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile.
    Hong HA; Hitri K; Hosseini S; Kotowicz N; Bryan D; Mawas F; Wilkinson AJ; van Broekhoven A; Kearsey J; Cutting SM
    Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28167669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
    Wullt M; Norén T; Ljungh A; Åkerlund T
    Clin Vaccine Immunol; 2012 Sep; 19(9):1552-4. PubMed ID: 22787196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
    Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
    Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
    Hussack G; Tanha J
    Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile.
    Murase T; Eugenio L; Schorr M; Hussack G; Tanha J; Kitova EN; Klassen JS; Ng KK
    J Biol Chem; 2014 Jan; 289(4):2331-43. PubMed ID: 24311789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.
    Roberts A; McGlashan J; Al-Abdulla I; Ling R; Denton H; Green S; Coxon R; Landon J; Shone C
    Infect Immun; 2012 Feb; 80(2):875-82. PubMed ID: 22144483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.
    Corthier G; Muller MC; Wilkins TD; Lyerly D; L'Haridon R
    Infect Immun; 1991 Mar; 59(3):1192-5. PubMed ID: 1900059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
    Monaghan TM; Robins A; Knox A; Sewell HF; Mahida YR
    PLoS One; 2013; 8(9):e74452. PubMed ID: 24058568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.